ERBB2 and lung carcinoma: We have shown that treatment with the rexinoid LG100268, but not bexarotene, decreased the number of immunosuppressive myeloid-derived suppressor cells and tumor-promoting macrophages in the lung cancer model21 and in the MMTV-Neu mouse model of HER2+ breast cancer53.